ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)

ChengDa Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	93.21	725.8	178.46	1,364	604.43	18.49
Trading Asset Securities	836.68	270.08	957.65	-	776.89	-
Cash & Short-Term Investments	929.89	995.88	1,136	1,364	1,381	18.49
Cash Growth	-5.39%	-12.34%	-16.70%	-1.26%	7369.47%	-60.67%
Accounts Receivable	113.72	111.33	97.75	126.68	111.13	93.08
Other Receivables	0.39	0.07	0.17	0.19	0.01	0.49
Receivables	114.11	111.39	97.92	126.87	111.14	93.56
Inventory	166.26	148.43	135.27	130.47	156.43	104.18
Prepaid Expenses	-	-	-	-	-	4.02
Other Current Assets	39.18	48.59	45.86	21.59	30.88	5.67
Total Current Assets	1,249	1,304	1,415	1,643	1,680	225.93
Property, Plant & Equipment	861.17	839	872.25	646.21	518.45	402.21
Long-Term Investments	61.07	68.48	7.41	30	30	-
Other Intangible Assets	36.42	37.16	36.51	33.85	34.58	39.83
Long-Term Deferred Tax Assets	14.93	13.34	8.06	4.29	4.23	2.79
Long-Term Deferred Charges	38.32	48.92	44.12	43.5	12.93	6.47
Other Long-Term Assets	68.7	38.68	52.94	54.6	41.95	6
Total Assets	2,330	2,350	2,436	2,455	2,322	683.23

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	199.3	164.63	189.23	139.89	77.82	57.83
Accrued Expenses	4.95	13.17	9.62	9.71	10.76	6.84
Short-Term Debt	-	-	-	-	-	54.06
Current Portion of Long-Term Debt	14.81	14.81	-	-	-	15
Current Income Taxes Payable	0.37	2.26	0.1	5.63	0.04	4.87
Current Unearned Revenue	1.96	3.35	2.79	11.87	6.18	7.82
Other Current Liabilities	3.74	4.74	5.03	4.43	4.74	1.37
Total Current Liabilities	225.12	202.97	206.76	171.53	99.54	147.78
Long-Term Debt	36.92	44.3	80.12	-	-	-
Long-Term Unearned Revenue	12.14	4.72	2.51	3.43	4.47	5.52
Long-Term Deferred Tax Liabilities	1.61	0.85	1.38	1.44	1.8	-
Total Liabilities	275.79	252.83	290.77	176.4	105.81	153.3

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	154.71	154.71	154.71	154.71	96.7	72.52
Additional Paid-In Capital	1,694	1,694	1,694	1,693	1,751	152.57
Retained Earnings	285.73	328.46	370.68	429.09	367.12	304.15
Treasury Stock	-57.07	-57.07	-57.07	-	-	-
Comprehensive Income & Other	-25.5	-25.5	-19.2	-	-	-
Total Common Equity	2,052	2,094	2,143	2,277	2,214	529.24
Minority Interest	2.55	2.61	2.64	1.8	1.68	0.68
Shareholders' Equity	2,054	2,097	2,146	2,279	2,216	529.93
Total Liabilities & Equity	2,330	2,350	2,436	2,455	2,322	683.23

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	51.73	59.11	80.12	-	-	69.06
Net Cash (Debt)	878.17	936.77	1,056	1,364	1,381	-50.56
Net Cash Growth	-5.03%	-11.29%	-22.58%	-1.26%	-	-
Net Cash Per Share	5.79	6.18	6.95	8.82	9.12	-0.44
Filing Date Shares Outstanding	152.08	151.47	151.47	154.71	154.71	116.04
Total Common Shares Outstanding	152.08	151.47	151.47	154.71	154.71	116.04
Working Capital	1,024	1,101	1,208	1,471	1,580	78.15
Book Value Per Share	13.49	13.83	14.15	14.72	14.31	4.56
Tangible Book Value	2,015	2,057	2,107	2,243	2,180	489.41
Tangible Book Value Per Share	13.25	13.58	13.91	14.50	14.09	4.22
Buildings	-	326.41	325.77	256.48	227.07	184.8
Machinery	-	703.54	701.73	430.36	328.86	313.05
Construction In Progress	-	108.19	101.46	179.17	153.53	70.7

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 8, 2026

Data Sources Report a data error